Literature DB >> 9403045

Sentinel lymphadenectomy for breast cancer in a community managed care setting.

J M Guenther1, M Krishnamoorthy, L R Tan.   

Abstract

PURPOSE: To evaluate the feasibility, accuracy, and reproducibility of intraoperative lymphatic mapping and sentinel lymphadenectomy (IOLM/SL) in the staging of breast cancer patients in a community managed care setting. PATIENTS AND METHODS: One hundred forty-five patients with primary breast cancer were prospectively studied over a 26-month period. They underwent vital dye injection at their primary breast cancer site. Lymphatic channels were traced to the sentinel lymph node, which was excised, serially sectioned, and examined. A level I and II axillary lymph node dissection and definitive breast surgery were then performed.
RESULTS: Sentinel nodes were identified in 103 of 145 procedures (71.0%). Sentinel and nonsentinel lymph nodes were concordant in 100 of 103 cases (97.1%). Three patients (9.7%) had falsely negative sentinel nodes; there were none in the last 80 patients. Of 28 positive sentinel nodes, 12 (42.9%) represented the only tumor-containing node within the axilla. Sentinel nodes were significantly more likely to contain tumor than nonsentinel nodes (33/50, 66.0% vs 54/467, 11.6%, P < 0.0001). IOLM/SL identified more micrometastases (< 2 mm) than standard axillary lymph node dissection (13/33, 39.6% vs 4/177, 2.2%, P < 0.001). Nine of 42 patients (21.4%) whose sentinel node could not be identified had five or more nodal metastases. Two of six patients with presumed Tis primaries had nodal metastases. DISCUSSION: IOLM/SL accurately identifies the sentinel lymph node(s) most likely to contain metastatic disease. A procedural learning curve was present. An unsuccessful IOLM/SL was a risk factor for considerable nodal metastases. IOLM/SL with a tumor-free sentinel node may obviate a formal axillary lymph node dissection. The technique was feasible, economical, and reproducible within the context of a community managed care facility, while not placing exacting demands on operating room, pathology, or nuclear medicine personnel.

Entities:  

Mesh:

Year:  1997        PMID: 9403045

Source DB:  PubMed          Journal:  Cancer J Sci Am        ISSN: 1081-4442


  23 in total

1.  Lessons learned from 500 cases of lymphatic mapping for breast cancer.

Authors:  A D Hill; K N Tran; T Akhurst; H Yeung; S D Yeh; P P Rosen; P I Borgen; H S Cody
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

2.  Credentialing for breast lymphatic mapping: how many cases are enough?

Authors:  H S Cody; A D Hill; K N Tran; M F Brennan; P I Borgen
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

Review 3.  Axillary staging of breast cancer and the sentinel node.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

4.  [Sentinel lymph node biopsy in breast cancer].

Authors:  A Rody; C Solbach; M Kaufmann
Journal:  Chirurg       Date:  2004-08       Impact factor: 0.955

5.  [Non-invasive imaging modalities for preoperative axillary lymph node staging in patients with breast cancer].

Authors:  K Wasser; A Schnitzer; J Brade; S O Schoenberg
Journal:  Radiologe       Date:  2010-11       Impact factor: 0.635

Review 6.  Sentinel lymph node mapping for primary breast cancer.

Authors:  Lori L Wilson; Armando E Giuliano
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

7.  Evaluation of breast lymphatic pathways with indocyanine green fluorescence imaging in patients with breast cancer.

Authors:  Yutaka Ogasawara; Hirokuni Ikeda; Mina Takahashi; Kensuke Kawasaki; Hiroyoshi Doihara
Journal:  World J Surg       Date:  2008-09       Impact factor: 3.352

8.  Ex vivo sentinel node mapping in carcinoma of the colon and rectum.

Authors:  J H Wong; S Steineman; C Calderia; J Bowles; T Namiki
Journal:  Ann Surg       Date:  2001-04       Impact factor: 12.969

9.  Predictors for nonsentinel node involvement in breast cancer patients with micrometastases in the sentinel lymph node.

Authors:  Archana Ganaraj; Joseph A Kuhn; Ronald C Jones; Michael D Grant; Valerie R Andrews; Sally M Knox; Georges J Netto; Basel Altrabulsi; Sheryl A Livingston; Todd M McCarty
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

10.  Subareolar blue dye only injection sentinel lymph node biopsy could reduce the numbers of standard axillary lymph node dissection in environments without access to nuclear medicine.

Authors:  Andreas Kavallaris; Oumar Camara; Ingo B Runnebaum
Journal:  J Cancer Res Clin Oncol       Date:  2007-11-20       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.